依普利酮上市没呢？

Is it listed? The new generation of selective aldosterone antagonist eplerenone was first launched in the United States in 2002 and applied for patent protection in China in 2006. It has not yet been launched in the country.

Eplerenone is a new type of selective aldosterone receptor antagonist that was approved for clinical use in 2002. Eplerenone can improve the quality of life of patients with left ventricular dysfunction (ejection fraction ≤ 40%). Clinical trials have proven that this product can also be used for congestive heart failure after acute myocardial infarction. Eplerenone can be used alone or in combination with other antihypertensive drugs for the treatment of hypertension.

Eplerenone is a new type of selective aldosterone receptor blocker that can effectively control hypertension, reduce damage to target organs such as the heart, brain and kidneys, and improve microalbuminuria in patients with type 2 diabetes. Eplerenone is a new type of selective aldosterone receptor antagonist. It has stronger aldosterone antagonism than spironolactone and has extremely low affinity for androgen and progesterone receptors. It has few adverse reactions and has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction. It has fewer adverse reactions and good tolerance. It is a good alternative drug to spironolactone.

It is a selective aldosterone receptor antagonist that only acts on mineralocorticoid receptors and does not act on androgen and progesterone receptors. Eplerenone treats patients with stage 1 and stage 2 hypertension with similar efficacy rates and reductions in systolic and diastolic blood pressure as enalapril. Eplerenone also has a good antihypertensive effect in patients with essential hypertension with low renin levels for whom angiotensin-converting enzyme inhibitors and angiotensin II receptor inhibitors are not effective. In addition, eplerenone can significantly reduce the ultrafiltration effect of glomeruli and reduce albuminuria in patients with hypertension. This renal protective effect is more obvious for hypertensive patients with diabetes.